Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Veracyte, Inc.

A Decade of SG&A: Gilead Sciences vs. Veracyte

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Gilead Sciences, Inc. and Veracyte, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Gilead Sciences, a titan in the industry, has seen its SG&A expenses grow by over 100% from 2014 to 2023, peaking at approximately $6 billion. This reflects its expansive operations and strategic investments. In contrast, Veracyte, a burgeoning player, has experienced a more modest increase, with expenses rising from around $40 million to $184 million, marking a 350% growth. This surge underscores Veracyte's aggressive scaling and market penetration efforts. As we delve into these figures, it becomes evident that while Gilead's growth is steady, Veracyte's rapid expansion highlights its ambition to carve a niche in the competitive biotech arena.

Key Insights

• Gilead's SG&A expenses doubled over the decade.
• Veracyte's expenses grew by 350%, indicating rapid expansion.